DOI:
10.1055/s-00000031
Klinische Monatsblätter für Augenheilkunde
LinksClose Window
References
Boettger MK, Klar J, Richter A. et al.
Topically administered regorafenib eye drops inhibit grade IV lesions in the non-human primate laser CNV model.
Invest Ophthalmol Vis Sci 2015;
56: 2294
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.